Raras
Buscar doenças, sintomas, genes...
Arterite de células gigantes
ORPHA:397CID-10 · M31.6CID-11 · 4A44.2OMIM 187360DOENÇA RARA

É uma inflamação dos vasos sanguíneos grandes, que atinge principalmente as artérias que saem do arco da aorta e, em especial, os ramos das artérias carótidas que ficam fora do crânio.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma inflamação dos vasos sanguíneos grandes, que atinge principalmente as artérias que saem do arco da aorta e, em especial, os ramos das artérias carótidas que ficam fora do crânio.

Pesquisas ativas
25 ensaios
185 total registrados no ClinicalTrials.gov
Publicações científicas
7.083 artigos
Último publicado: 2026 Apr 16

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
8.9
Germany
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: M31.6
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
9 sintomas
❤️
Coração
6 sintomas
🧠
Neurológico
5 sintomas
🩸
Sangue
4 sintomas
🫃
Digestivo
3 sintomas
🦴
Ossos e articulações
3 sintomas

+ 29 sintomas em outras categorias

Características mais comuns

90%prev.
Mastigação prejudicada
Muito frequente (99-80%)
90%prev.
Fadiga
Muito frequente (99-80%)
90%prev.
Perda de peso
Muito frequente (99-80%)
90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Isquemia cerebral
Muito frequente (99-80%)
90%prev.
Concentração elevada de proteína C-reativa circulante
Muito frequente (99-80%)
72sintomas
Muito frequente (10)
Frequente (15)
Ocasional (44)
Sem dados (3)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 72 características clínicas mais associadas, ordenadas por frequência.

Mastigação prejudicadaImpaired mastication
Muito frequente (99-80%)90%
FadigaFatigue
Muito frequente (99-80%)90%
Perda de pesoWeight loss
Muito frequente (99-80%)90%
FebreFever
Muito frequente (99-80%)90%
Isquemia cerebralCerebral ischemia
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico7.083PubMed
Últimos 10 anos200publicações
Pico2026122 papers
Linha do tempo
2026Hoje · 2026🧪 1994Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

4 genes identificados com associação a esta condição. Padrão de herança: Multigenic/multifactorial.

HLA-BHLA class I histocompatibility antigen, B alpha chainMajor susceptibility factor inTolerante
FUNÇÃO

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:23209413, PubMed:25808313, PubMed:29531227, PubMed:9620674). May also present self-peptides derived from the

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
E3 ubiquitin ligases ubiquitinate target proteins
MECANISMO DE DOENÇA

Stevens-Johnson syndrome

A rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
8283.6 TPM
Baço
6025.1 TPM
Linfócitos
5071.2 TPM
Pulmão
4631.0 TPM
Intestino delgado
2873.0 TPM
OUTRAS DOENÇAS (7)
obsolete pulmonary arterial hypertension associated with connective tissue diseaseTakayasu arteritistemporal arteritisStevens-Johnson syndrome
HGNC:4932UniProt:P01889
P4HA2Prolyl 4-hydroxylase subunit alpha-2Major susceptibility factor inTolerante
FUNÇÃO

Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins

LOCALIZAÇÃO

Endoplasmic reticulum lumen

VIAS BIOLÓGICAS (2)
Maturation of DENV proteinsCollagen biosynthesis and modifying enzymes
MECANISMO DE DOENÇA

Myopia 25, autosomal dominant

A refractive error of the eye, in which parallel rays from a distant object come to focus in front of the retina, vision being better for near objects than for far.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
50.8 TPM
Aorta
21.8 TPM
Útero
20.4 TPM
Pulmão
17.5 TPM
Artéria coronária
16.3 TPM
OUTRAS DOENÇAS (2)
myopia 25, autosomal dominanttemporal arteritis
HGNC:8547UniProt:O15460
HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainMajor susceptibility factor inRestrito
FUNÇÃO

A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneLysosome membraneLate endosome membraneAutolysosome membrane

VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1832.6 TPM
Pulmão
1234.8 TPM
Baço
990.6 TPM
Intestino delgado
607.2 TPM
Nervo tibial
598.3 TPM
OUTRAS DOENÇAS (16)
narcolepsy-cataplexy syndromefollicular lymphomaVogt-Koyanagi-Harada diseasepediatric multiple sclerosis
HGNC:4948UniProt:P01911
PTPN22Tyrosine-protein phosphatase non-receptor type 22Major susceptibility factor inTolerante
FUNÇÃO

Acts as a negative regulator of T-cell receptor (TCR) signaling by direct dephosphorylation of the Src family kinases LCK and FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV, VCP and other key signaling molecules (PubMed:16461343, PubMed:18056643). Associates with and probably dephosphorylates CBL. Dephosphorylates LCK at its activating 'Tyr-394' residue (PubMed:21719704). Dephosphorylates ZAP70 at its activating 'Tyr-493' residue (PubMed:16461343). Dephosphorylates the immune system a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
Phosphorylation of CD3 and TCR zeta chainsTranslocation of ZAP-70 to Immunological synapse
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
50.6 TPM
Baço
13.9 TPM
Sangue
12.7 TPM
Intestino delgado
9.6 TPM
Pulmão
8.7 TPM
OUTRAS DOENÇAS (6)
systemic lupus erythematosusVogt-Koyanagi-Harada diseaseoligoarticular juvenile idiopathic arthritisrheumatoid factor-negative juvenile idiopathic arthritis
HGNC:9652UniProt:Q9Y2R2

Medicamentos aprovados (FDA)

2 medicamentos encontrados nos registros da FDA americana.

💊 Tofidence (TOCILIZUMAB)
💊 Rinvoq (UPADACITINIB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

74 variantes patogênicas registradas no ClinVar.

🧬 HLA-B: GRCh37/hg19 6p21.33(chr6:30944923-31867966)x1 ()
🧬 HLA-B: NM_005514.8(HLA-B):c.299A>T (p.Glu100Val) ()
🧬 HLA-B: NM_005514.8(HLA-B):c.1011A>T (p.Ser337=) ()
🧬 HLA-B: NM_005514.8(HLA-B):c.*4+35C>G ()
🧬 HLA-B: NM_005514.8(HLA-B):c.*4+47T>A ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado2
3Fase 33
2Fase 22
·Pré-clínico13
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Arterite de células gigantes

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

17 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

185 ensaios clínicos encontrados, 25 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
3.680 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 3.680

#1

Polymyalgia Rheumatica.

The New England journal of medicine2026 Mar 12

Polymyalgia rheumatica is an inflammatory condition that affects persons older than 50 years of age and is characterized by pain in both shoulders with or without hip or neck pain (or both) and with pronounced morning stiffness. The condition is typically diagnosed on the basis of these hallmark symptoms along with elevated inflammation markers (erythrocyte sedimentation rate and C-reactive protein level) and the ruling out of other conditions including giant-cell arteritis. Glucocorticoids are the primary treatment, which provide rapid symptom relief. The initial dose, usually 12.5 to 25 mg of prednisone equivalent daily, is gradually reduced, ideally over 12 months or less, although the disease course varies and polymyalgia rheumatica may persist for a longer duration. Relapses are common and sometimes warrant the use of interleukin-6 receptor inhibitors or methotrexate to minimize glucocorticoid exposure.

#2

Systematic Review and Meta-Analysis for JCS 2026 Guideline on Management of Large-Vessel Vasculitis.

Circulation journal : official journal of the Japanese Circulation Society2026 Feb 14

To provide evidence from randomized controlled trials (RCTs) for large-vessel vasculitis (LVV), including Takayasu arteritis (TAK) and giant cell arteritis (GCA), to inform the forthcoming 2026 Japanese Circulation Society (JCS) clinical practice guideline. We drafted 4 and 7 clinical questions for TAK and GCA, respectively. A systematic review (SR) of RCTs was conducted using PubMed, CENTRAL, EMBASE, and the Japan Medical Abstracts Society through March 2024. Assessed with the GRADE approach, the certainty of evidence was very low for the most critical outcomes, low for some outcomes, and moderate for only 1 outcome. Evidence for TAK was limited. Tocilizumab (TCZ) resulted in a numerically lower relapse rate vs. placebo (risk ratio (RR) 0.73, 95% confidence interval (CI) 0.39-1.37) and was similar to adalimumab. No clear difference between mycophenolate mofetil (MMF) and methotrexate (MTX), or between abatacept (ABA) and placebo was observed. In GCA, TCZ reduced relapse (RR 0.29, 95% CI 0.09-0.98) and increased remission (RR 3.56, 95% CI 2.29-5.54) over placebo at 52 weeks. Tumor necrosis factor inhibitor, ABA, and MTX showed no benefit in cranial GCA. Serious adverse events were comparable between treatment groups. Geographic variation and differences in entry criteria were noted. This SR was comprehensive synthesis of evidence from RCTs for LVV therapies to support the 2026 JCS guideline.

#3

Hydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol.

BMJ open2026 Feb 04

Glucocorticoid therapy is prescribed for a variety of inflammatory conditions and is associated with severe adverse effects. A glucocorticoid withdrawal syndrome (GWS) may occur after prolonged glucocorticoid treatment-with or without biochemical glucocorticoid-induced adrenal insufficiency (GIAI). Previously, GWS was not considered an entity, probably due to the overlap between symptoms of GWS and GIAI. The Addison's disease-specific quality of life questionnaire (AddiQoL-30) is a validated tool for quantifying symptoms of adrenal insufficiency resembling GWS. In the present study, we test the hypothesis that patients with a low AddiQoL-30 score and/or low cortisol response to a short Synacthen test (SST), after cessation of prednisolone treatment, may benefit from low-dose hydrocortisone therapy without increasing the risk of metabolic and cardiovascular disease during prolonged cortisol exposure. REPLACE is a multi-centre, double-blinded, placebo-controlled randomised controlled trial in patients with polymyalgia rheumatica or giant cell arteritis after cessation of prednisolone treatment. Criteria for randomisation are an AddiQoL-30 score ≤85 and/or plasma cortisol response to SST, 30-min p-cortisol >100 and <420 nmol/L. Patients will be randomised to oral hydrocortisone (10 mg two times a day) or placebo for 16 weeks. Baseline and follow-up examinations comprise AddiQoL-30 questionnaire, SST, blood samples, standardised blood pressure, physical function tests and assessment of bone quality and body composition. At baseline, two comparator groups include: (1) patients with a SST-stimulated cortisol ≥420 nmol/L and AddiQoL-30 score >85; and (2) patients with a SST-stimulated cortisol ≤100 nmol/L. The study is conducted in accordance with the Declaration of Helsinki, registered at the Clinical Trials Information System (CTIS: 2024-513822-53-00) and Clinicaltrials.gov (NCT05193396), and publications will be in accordance with the recommendations of the International Committee of Medical Journal Editors. The trial is monitored by local independent Good Clinical Practice units and overseen by the Danish Data Protection Agency (journal no. 21/27119), the Regional Committees on Health Research Ethics for Southern Denmark (project ID: S-20210076), the Danish Patient Safety Authority and the Danish Medicines Agency. NCT05193396.

#4

Pulmonary artery aneurysm as a rare manifestation of giant cell arteritis.

BMJ case reports2026 Jan 27

A female patient in her 70s with a remote history of vocal cord paralysis was incidentally found to have a pulmonary artery aneurysm on a chest CT. Serial imaging performed over 3 years noted enlargement beyond 5.5 cm, prompting surgical repair. Histopathological examination revealed granulomatous arteritis with multinucleated giant cells and disruption of the elastic lamina, consistent with large-vessel giant cell arteritis (GCA). The patient was treated with corticosteroids and subsequently transitioned to subcutaneous tocilizumab, achieving postoperative stability on imaging and normalisation of inflammatory markers.This case highlights an unusual presentation of GCA with isolated pulmonary artery involvement, underscoring the diagnostic value of surgical tissue biopsy and the importance of considering vasculitis in aneurysmal disease, even in the absence of systemic manifestations.

#5

Scalp necrosis and visual loss in giant cell arteritis: the importance of recognising atypical cutaneous clues.

Practical neurology2026 Jan 06

A 70-year-old woman had presented with electric shock-like left hemifacial pain, with bilateral forehead skin plaques, diagnosed as shingles. 2 weeks later, she suddenly lost vision in the left eye. She had left optic disc oedema and bilateral necrotic-looking scalp lesions. Temporal artery biopsy was consistent with active temporal arteritis. Giant cell arteritis (GCA) may rarely present with scalp necrosis due to vasculitis of the facial arteries; the resulting hemifacial pain and atypical scalp rash may be misinterpreted as varicella zoster infection, delaying urgent intervention for GCA.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC5.037 artigos no totalmostrando 195

2026

Racial and Ethnic Disparities in Severe Ischemic Manifestations and Tocilizumab Use Among Patients With Giant Cell Arteritis: A Nationwide Retrospective Cohort Study Using TriNetX.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2026

Advances in the management of giant cell arteritis-aortitis: biologic therapies and beyond - a narrative review.

Expert opinion on biological therapy
2026

Takayasu and Giant Cell Arteritis Unmasked by Vedolizumab as Paradoxical Reactions: Two Case Reports.

ACR open rheumatology
2026

Added value of [⁶⁸Ga]Ga-FAPI-46 PET/CT in cranial giant cell arteritis missed by [¹⁸F]FDG PET/CT.

European journal of nuclear medicine and molecular imaging
2026

Methylprednisolone pulses are associated with faster remission in Giant Cell Arteritis: a multicentre inception cohort study.

Arthritis research &amp; therapy
2026

Giant cell arteritis-associated temporomandibular joint arthritis confirmed by imaging.

Rheumatology advances in practice
2026

Regarding the Prognostic Value of the HALP Score in Giant Cell Arteritis and Polymyalgia Rheumatica.

International journal of rheumatic diseases
2026

Advances in the use of Janus kinase inhibitors.

Current opinion in rheumatology
2026

Giant cell arteritis and atherosclerosis: coexistence or causality?

Clinical and experimental rheumatology
2026

Giant cell arteritis, neuralgia, dental pain.

British dental journal
2026

Large-Vessel Vasculitis With Autoimmune Myelodysplastic Syndrome: An Uncommon Case of Large-Vessel Vasculitis With Cytopenia That Is Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic Syndrome (VEXAS) Negative.

Cureus
2026

Intracranial Giant Cell Arteritis Progressing despite Treatment with High Doses of Corticosteroids: Case Report.

Case reports in ophthalmology
2026

Echoes of Inflammation: Cardiovascular Risk in Giant Cell Arteritis.

European journal of preventive cardiology
2026

Systemic Conditions Associated with Primary Open-Angle Glaucoma and Normal Tension Glaucoma in a Large US Adult Cohort.

Ophthalmic epidemiology
2026

Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis.

Open medicine (Warsaw, Poland)
2026

Giant Cell Arteritis With Medin-Derived Amyloid (AMed) Deposition in a Patient With COVID-19: An Autopsy Case.

Pathology international
2026

Association of Autoimmune Diseases With Pancreatic Cancer: A Nationwide Follow-Up Study From Sweden.

Cancer medicine
2026

Alternating Amaurosis Fugax: A Critical Warning Sign of Giant Cell Arteritis.

The American journal of medicine
2026

Halo sign is not always due to giant cell arteritis.

Internal medicine journal
2026

Ultrasound, PET/CT or temporal artery biopsy for giant cell arteritis? A prospective diagnostic accuracy study (the GAME-study).

Acta ophthalmologica
2026

Changing Trends in Temporal Artery Biopsy Rates in Australia: A Nationwide Study Over 31 Years.

ANZ journal of surgery
2026

Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis.

ACR open rheumatology
2026

Treatment-resistant arterial hypertension revealing giant cell arteritis: A case report.

The American journal of medicine
2026

A case of large-vessel giant cell arteritis onset in a patient over 90 years old: Diagnostic challenge in differentiating from an infectious aneurysm.

Journal of cardiology cases
2026

Giant cell arteritis-polymyalgia rheumatica spectrum disease (GPSD): Relation with neoplasms and possible role as a paraneoplastic syndrome.

Reumatologia clinica
2026

A Five-Step Approach to Acute Vision Loss: A Practical Narrative Review for Clinicians.

Clinical ophthalmology (Auckland, N.Z.)
2026

Calprotectin and serum amyloid A for disease activity assessment in giant cell arteritis and polymyalgia rheumatica: results from a prospective single-centre cohort study.

Rheumatology international
2026

Risk factors for acute coronary syndrome in patients with giant cell arteritis: a scoping review.

Therapeutic advances in musculoskeletal disease
2026

Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database.

Arthritis research &amp; therapy
2026

[Autoimmune hearing loss in giant cell arteritis: a clinical case].

Vestnik otorinolaringologii
2026

An aneurysm without a headache: large-vessel giant cell arteritis presenting solely as aortic aneurysm.

Journal of cardiothoracic surgery
2026

Absolute quantification of microRNA miR-875-5p in temporal artery biopsies and its biomarker potential for giant cell arteritis.

Frontiers in immunology
2026

Crowned Dens Syndrome Mimicking Atlantoaxial Infection in a Patient With Systemic Sclerosis: A Case Report.

Case reports in rheumatology
2026

Orbital MRI for diagnosing giant cell arteritis in cases of anterior ischaemic optic neuropathy.

RMD open
2026

Prognosis and long term outcome of stenotic large vessel involvement in giant cell arteritis.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Large Vessel Vasculitis Primarily Affecting the Lower Extremities: A Case Series and Literature Review.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2026

Is there a seasonal pattern in giant cell arteritis? Revisiting the evidence in a large monocentric cohort over 30 years.

Seminars in arthritis and rheumatism
2026

Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients.

Drugs &amp; aging
2026

Clinical characteristics of giant cell arteritis with ocular involvement: A single-centre retrospective study.

Modern rheumatology
2026

[The retinal artery occlusion].

Klinische Monatsblatter fur Augenheilkunde
2026

Stroke characteristics in giant cell arteritis and Takayasu arteritis: A multicenter retrospective cohort study of 108 patients.

Seminars in arthritis and rheumatism
2026

IFNL4 genotype is associated with hepatitis A virus infection findings from a focused phenotype study in the UK Biobank Cohort.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
2026

Systemic Amyloidosis Masquerading as Giant Cell Arteritis.

Ophthalmology
2026

Understanding the patient experience of newly diagnosed giant cell arteritis.

Rheumatology advances in practice
2026

Systematic Review and Meta-Analysis for JCS 2026 Guideline on Management of Large-Vessel Vasculitis.

Circulation journal : official journal of the Japanese Circulation Society
2026

A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis.

Annals of the rheumatic diseases
2026

Diagnostic Challenges and Modern Therapeutic Strategies in Giant Cell Arteritis.

Diagnostics (Basel, Switzerland)
2026

Long-Term Follow-Up in Patients with Large-Vessel Vasculitis Applying Extracranial and Transcranial Duplex Sonography.

Diagnostics (Basel, Switzerland)
2026

Extracranial subcutaneous nodules in giant cell arteritis: response to baricitinib.

Clinical and experimental rheumatology
2026

Re: Chauhan et al.: Risk of giant cell arteritis among patients presenting with undifferentiated noninfectious uveitis (Ophthalmology. 2025;132:1180-1182).

Ophthalmology
2026

Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experience.

RMD open
2026

Autoantibodies and B Cells in Takayasu Arteritis and Giant Cell Arteritis: Comparative Insights into Large-Vessel Vasculitis.

The Tohoku journal of experimental medicine
2026

Patient experiences of PMR: a qualitative narrative literature review.

Rheumatology advances in practice
2026

Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritis.

Arthritis research &amp; therapy
2026

Color Doppler Ultrasound Versus Magnetic Resonance Imaging for Diagnosing Giant Cell Arteritis: A Systematic Review and Meta-Analysis.

Cureus
2026

A corona-like distribution and patchy pattern of cerebellar infarcts identify patients with giant cell arteritis.

Therapeutic advances in neurological disorders
2026

[Large vessel vasculitis without aortitis in giant cell arteritis: About 4 cases].

La Revue de medecine interne
2026

Anterior Ischemic Optic Neuropathy Associated with Acute Severe Anemia Due to Myelodysplastic Syndrome (MDS): A Case Report.

Neuro-ophthalmology (Aeolus Press)
2026

Giant Cell Arteritis/Polymyalgia Rheumatica and Atypical Pulmonary Carcinoid Tumor: A Paraneoplastic Syndrome?

The American journal of case reports
2026

Dynamic vascular changes on long-term ultrasound monitoring predict relapse in large-vessel giant cell arteritis.

Arthritis research &amp; therapy
2026

Hydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol.

BMJ open
2026

The characteristics of giant cell arteritis patients that went blind in spite of treatment: case based narrative literature review.

Rheumatology international
2026

Therapeutic management of inflammatory heart diseases.

Pharmacology &amp; therapeutics
2026

Performance of the Southend Giant Cell Arteritis Probability Score in a Single-Centre New Zealand Fast-Track Pathway.

International journal of rheumatic diseases
2026

Easily Missed? Giant cell arteritis.

BMJ (Clinical research ed.)
2026

High-resolution imaging of giant cell arteritis with photon-counting computed tomography.

Annals of the rheumatic diseases
2026

Pulmonary artery aneurysm as a rare manifestation of giant cell arteritis.

BMJ case reports
2026

Paracentral Acute Middle Maculopathy Associated with Arteritic Anterior Ischemic Optic Neuropathy in a Case of Giant Cell Arteritis.

Klinische Monatsblatter fur Augenheilkunde
2026

Erdheim-Chester disease mimicking IgG4-related disease.

Modern rheumatology case reports
2026

A rare pair: two cases of clinically isolated pulmonary artery aneurysm.

Therapeutic advances in cardiovascular disease
2026

Barriers to immediate corticosteroid treatment in suspected giant cell arteritis with visual symptoms: insights from a tertiary eye care unit.

BMC ophthalmology
2025

Cardiovascular Risk Factors and Antiphospholipid Antibodies in Giant Cell Arteritis-Related Thrombosis.

Archives of rheumatology
2026

The real-world experience of combined cranial and large vessel 18F-FDG-PET/CT in the investigation of giant cell arteritis.

Clinical rheumatology
2026

Prevalence of diplopia among giant cell arteritis patients: a systematic review and meta-analysis.

Eye (London, England)
2026

OCT and OCT-A Findings in Giant Cell Arteritis: PAMM as a Specific Ischemic Marker.

Retina (Philadelphia, Pa.)
2026

The Association of Polymyalgia Rheumatica and Giant Cell Arteritis With COVID-19 Vaccination: A Systematic Review.

Clinical medicine insights. Arthritis and musculoskeletal disorders
2025

Giant Cell Arteritis Mimicking Temporomandibular Disorder: Diagnostic Value of Temporal Artery Halo Sign.

Journal of clinical and experimental dentistry
2026

Advances in management of giant cell arteritis.

Internal medicine journal
2026

Concurrent Thyroid Tumor in an Elderly Patient with Giant Cell Arteritis: A Case Report.

The Tohoku journal of experimental medicine
2026

Re: comment on: Miedany et al. response letter: Beyond the symptoms: personalizing giant cell arteritis care through multidimensional patient reported outcome measure. Volume 75, December 2025, 152844.

Seminars in arthritis and rheumatism
2026

Distinguishing Takayasu Arteritis and Giant Cell Arteritis Based on Large-Vessel Involvement Patterns.

Yonsei medical journal
2025

Giant Cell Arteritis With Central Nervous System Vasculitis Presenting As Binocular Diplopia and Ptosis due to Third Cranial Nerve Palsy.

Cureus
2025

Giant Cell Arteritis Following Dental Procedure.

Cureus
2026

Automated detection of giant cell arteritis from temporal artery biopsy specimens using deep learning approaches.

Scientific reports
2026

Cardiovascular risk among Giant cells arteritis patients.

European journal of preventive cardiology
2026

Ischemia of the Tongue and Scalp as an Uncommon Presentation of Giant Cell Arteritis.

European journal of case reports in internal medicine
2025

Atypical Oral Presentation of Giant Cell Arteritis With Subsequent Middle Cerebral Artery Involvement.

Cureus
2026

Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.

Arthritis care &amp; research
2026

Exploring the Association Between Autoimmune and Inflammatory Diseases and Uveitis.

American journal of ophthalmology
2026

In synergy with interferon-gamma, interleukin-17 activates vascular stromal cells towards a pro-inflammatory profile in giant cell arteritis.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Fast-Track Clinics and Visual Outcomes in Giant Cell Arteritis: A Systematic Review and Meta-Analysis.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2026

Imaging-guided stratification in giant cell arteritis: prognostic and therapeutic implications.

Therapeutic advances in musculoskeletal disease
2025

Clinical Decision-Making Case: A Giant Headache.

Journal of education &amp; teaching in emergency medicine
2026

Potential clinical utility of quantitative 18F-FDG PET/CT parameters in evaluating vascular inflammation in giant cell arteritis.

Clinical and experimental rheumatology
2026

COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS.

Seminars in arthritis and rheumatism
2026

Scalp necrosis and visual loss in giant cell arteritis: the importance of recognising atypical cutaneous clues.

Practical neurology
2025

A Case of CRP-Negative Giant Cell Arteritis Detected by Contrast-Enhanced Orbital MRI.

Cureus
2026

Current clinical practice trends in giant cell arteritis diagnosis and management: a national survey of Australian rheumatologists and rheumatology trainees.

Internal medicine journal
2026

Patient perspectives on life impact and unmet needs in giant cell arteritis and polymyalgia rheumatica: insights from social media.

Rheumatology advances in practice
2025

When the Eyes Deceive: Uncommon Ophthalmic Presentation of Giant Cell Arteritis.

Cureus
2025

Bilateral Optic Sheath Enhancement in Giant Cell Arteritis (GCA) Presenting With Occipital Neuralgia-Like Symptoms.

Cureus
2026

How common is vasculitis: what do population-based data tell us?

Current opinion in rheumatology
2026

Sex differences among patients with giant cell arteritis: insights from the Spanish ARTESER Registry.

Rheumatology (Oxford, England)
2026

Varicella Zoster Virus in Giant Cell Arteritis: Evidence From a Systematic Review and Meta-Analytic Synthesis.

Reviews in medical virology
2026

Treatment Patterns and Clinical Outcomes for Patients Living with Active Giant Cell Arteritis in Canada.

Rheumatology and therapy
2026

Cellular senescence in giant cell arteritis and polymyalgia rheumatica: From mechanisms to therapeutic opportunities.

European journal of clinical investigation
2025

Thoracic Aortic Aneurysm and Giant Cell Arteritis: Clarifying the Link.

Aorta (Stamford, Conn.)
2026

Neuro-ophthalmic Manifestations of Multiple Sclerosis.

International ophthalmology clinics
2026

Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits.

The Lancet. Rheumatology
2025

Bilateral Occipital Lobe Infarcts, A Rare Cause of Vision Loss in Giant Cell Arteritis.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2025

Performance of Diagnostic Examinations for Giant Cell Arteritis and Subtypes: A Multicenter Japanese Study.

International journal of rheumatic diseases
2026

Overlapping macrophage immune profiles in polymyalgia rheumatica and giant cell arteritis.

Rheumatology (Oxford, England)
2026

Management of extracranial carotid artery pseudoaneurysms.

Journal of vascular surgery cases and innovative techniques
2025

Markers of Giant Cell Arteritis in Patients Presenting With Ischemic Stroke: A Scoping Review.

European journal of neurology
2026

Giant Cell Arteritis Causing Isolated Pulmonary Artery Aneurysm.

JACC. Case reports
2025

The Use of Vessel Wall Imaging for Making an Early Diagnosis of Giant Cell Arteritis in a Case with Cerebral Infarction.

Internal medicine (Tokyo, Japan)
2025

Temporal Artery Biopsy: A 10-Year Multi-centre Review of Current Practice.

Cureus
2026

The influence of baseline aortitis on aortic dilation risk in GCA: a multicentre imaging study.

Rheumatology (Oxford, England)
2026

Mönckeberg medial calcific sclerosis mimicking temporomandibular disorder and giant cell arteritis: a case report.

Quintessence international (Berlin, Germany : 1985)
2025

Infographic: GiACTA - Trial of Tocilizumab in Giant-Cell Arteritis.

Eye (London, England)
2025

Giant Cell Aortitis and Tuberculosis: Coincidence or a Causal Link?

Cureus
2025

Fast-track pathway for giant cell arteritis: Improved visual outcomes and reduced healthcare costs.

PloS one
2026

Large Vessel Vasculitis: Multimodality Imaging Findings and Technical Principles.

Radiographics : a review publication of the Radiological Society of North America, Inc
2025

Identification of BHLHE40-expressing T cells in giant cell arteritis amplified by interleukin-1.

Immunological medicine
2025

[Chinese expert consensus on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors].

Zhonghua nei ke za zhi
2025

Giant cell arteritis in clinical practice: beyond GiACTA.

Clinical and experimental rheumatology
2026

Eosinophilic granulomatosis with polyangiitis mimicking giant cell arteritis.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2025

The effectiveness and safety of leflunomide in the treatment of giant cell arteritis: a systematic review and meta-analysis.

Rheumatology advances in practice
2025

Unusual Presentation of Giant Cell Arteritis With Localised Temporal Artery Aneurysm.

Cureus
2025

A Rare Case of Giant Cell Arteritis Affecting Two Giants: Pulmonary and Root of Aorta Aneurysm.

Clinical case reports
2026

Identification of therapeutic targets for giant cell arteritis through integrated analysis of multi-omics datasets.

Hepatobiliary &amp; pancreatic diseases international : HBPD INT
2026

Characteristics of patients with major relapse in giant cell arteritis: a multicenter case-control study.

Clinical rheumatology
2025

Uncommon coexistence of giant cell arteritis and SIADH: case reports and literature review.

Internal and emergency medicine
2026

Patient characteristics, disease manifestations and diagnostic findings of consecutive patients suspected of Giant Cell Arteritis (GCA) - retrospective experience from a fast-track clinic in Israel.

Clinical rheumatology
2025

The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy.

Biomolecules
2025

The Role of Imaging in Monitoring Large Vessel Vasculitis: A Comprehensive Review.

Biomolecules
2025

A Case of Giant Cell Arteritis Presenting With a Hyperechoic Wall Thickening on Temporal Artery Ultrasonography.

Cureus
2025

Mortality in isolated polymyalgia rheumatica and giant cell arteritis is not increased: evidence from cohort data.

Clinical and experimental medicine
2025

Nocardia farcinica Brain Abscess in a Glucocorticoid-Treated Patient with Giant-Cell Arteritis: A Case Report.

The American journal of case reports
2026

Study on the chemokine CXCL10 in serum for its value in GCA-PMR spectrum disease stratification.

Clinical rheumatology
2025

Can HALP Score Predict the Prognosis of Patients With Giant Cell Arteritis and Polymyalgia Rheumatica?

International journal of rheumatic diseases
2025

The Role of FDG-PET in the Diagnosis and Monitoring of Large-Vessel Vasculitis.

Current rheumatology reports
2025

Diagnostic and prognostic utility of complete blood count-derived ratios in giant cell arteritis: a retrospective fast-track clinic cohort study.

Rheumatology international
2026

Recurrent vertebrobasilar stroke in giant cell arteritis associated with progressive prostate carcinoma: a case report and literature review.

Clinical rheumatology
2025

Current Insights and Future Perspectives for the Use of Serological Biomarkers in Polymyalgia Rheumatica.

Journal of inflammation research
2025

Early-stage cost-utility analysis of novel diagnostic tests for giant cell arteritis: a modelling study in UK secondary care.

BMJ open
2025

Unmasking the Great Mimic: An Atypical Presentation of Giant Cell Arteritis With Recurrent and Isolated Diplopia.

Cureus
2025

Increased expression of Toll-like receptors and associated alarmins in temporal arteries of patients with giant cell arteritis.

Molecular medicine (Cambridge, Mass.)
2025

Ultrasound localisation microscopy reveals mural neovascularisation to diagnose and track giant cell arteritis.

Annals of the rheumatic diseases
2025

Tocilizumab monotherapy versus combined in aortitis associated with giant cell arteritis: Factors associated with imaging remission in a multicenter open-label study of 196 patients.

Seminars in arthritis and rheumatism
2025

[Lingual symptoms as an initial manifestation of giant cell arteritis].

Semergen
2025

Optical coherence tomography angiography detects retinal microvascular changes in giant cell arteritis: the potential protective role of aortitis.

RMD open
2025

An Unusual Case of Cerebral Venous Sinus Thrombosis With Negative D-dimer Mimicking Giant Cell Arteritis.

Cureus
2026

Polymyalgia rheumatica and giant cell arteritis: lumping versus splitting.

Rheumatology (Oxford, England)
2025

Syphilitic Cardiac and Vascular Disease: A Comprehensive Review.

Cardiology in review
2025

[Giant cell arteritis (GCA) presenting as isolated paracentral acute middle maculopathy (PAMM)].

Journal francais d'ophtalmologie
2026

Treatment and evolution of 134 patients with aortitis and periaortitis: experience of a third-level university hospital.

Internal and emergency medicine
2025

You Never Think Enough About Giant Cell Arteritis.

Ocular immunology and inflammation
2025

A Case Report of Bilateral Sequential Central Retinal Artery Occlusion in Occult Giant Cell Arteritis: The Eyes Are Windows to Systemic Disease.

Cureus
2025

Medium-sized vessel uptake on PET/CT as a clue to extracranial giant cell arteritis.

Revista clinica espanola
2025

Giant Cell Arteritis Manifesting as Area Postrema Syndrome: A Case Report.

Cureus
2026

Vasculitis syndromes: large vessel vasculitides and ANCA-associated vasculitides from a neuroradiologist's perspective.

Japanese journal of radiology
2026

Risk of hospitalization with pneumonia in patients with giant cell arteritis and anti-neutrophil cytoplasmic antibody associated vasculitis.

Rheumatology (Oxford, England)
2025

Can Vitamin D Reduce Glucocorticoid-Induced Adverse Effects in Patients with Giant Cell Arteritis? Results from 1568 Patients in the Spanish ARTESER Registry.

Nutrients
2025

Temporal artery biopsy and temporal artery ultrasound inter-rater agreement for the diagnosis of giant cell arteritis: an ancillary analysis from the multicentre prospective ECHORTON study.

Rheumatology international
2025

The Interplay Between Varicella-Zoster Virus and Giant Cell Arteritis: An In-Depth Narrative Review.

Cureus
2025

Predictors of giant cell arteritis in patients with polymyalgia rheumatica in southern Sweden-a retrospective study.

Rheumatology advances in practice
2025

Refractory Hypothyroidism: Unexpected Outcome During Treatment of Giant Cell Arteritis.

Clinical case reports
2025

Reviewer Comment on Rizwan et al. "CT Angiography of the Head for the Initial Assessment of Giant Cell Arteritis: Presenting Symptoms, Biopsy Outcomes and Alternative Diagnosis".

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2025

[Giant cell arteritis - When should the GP consider it?].

MMW Fortschritte der Medizin
2026

Vascular uptake on 18F-FDG PET/CT predicts relapse in new-onset PMR.

Rheumatology (Oxford, England)
2025

Seasonality and latitude as linked environmental factors in giant cell arteritis incidence: a systematic review and meta-analysis.

Rheumatology international
2025

An Atypical Presentation of Giant Cell Arteritis in an Elderly Patient: Diplopia and Fever Masked by Pneumonia.

Cureus
2025

Birdshot Chorioretinopathy in a Patient on Tocilizumab for the Treatment of Giant Cell Arteritis.

Case reports in ophthalmological medicine
2025

Halo Sign on Temporal Artery Ultrasound Aids in Prompt Diagnosis of Giant Cell Arteritis.

Methodist DeBakey cardiovascular journal
2026

Spatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response.

Annals of the rheumatic diseases
2025

Serum interleukin-1 receptor antagonist levels are a useful marker of disease activity and risk of relapse in large vessel vasculitis.

Cytokine
2025

Mature CD209+CD83+CCR7+ dendritic cells infiltrate the arterial wall in giant cell arteritis and derive from in-situ monocyte differentiation.

Scientific reports
2026

Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment.

Annals of the rheumatic diseases
2025

Case Report: Transient monocular vision loss with isolated paracentral acute middle maculopathy on optical coherence tomography: beware of giant cell arteritis!

Frontiers in neurology
2025

Oculoplastics and Augmented Intelligence: A Literature Review.

Journal of clinical medicine
2025

Modern Management of Isolated Polymyalgia Rheumatica.

Rheumatology and therapy
2025

Monocytes/Macrophages in Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease.

Aging and disease
2025

New versus old: comparison of the 2022 ACR/EULAR versus the 1990 ACR classification criteria for giant cell arteritis in a real-world cohort.

Rheumatology international
2025

Multimodality imaging of giant cell arteritis.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2026

Treatment of systemic vasculitis.

Current opinion in rheumatology
2025

Immediate versus gradual TocilizuMab discontinuAtion in GIant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial.

BMJ open
2025

Siegrist Streaks in a Case of Biopsy-negative Giant Cell Arteritis: A Case Report.

Ophthalmic surgery, lasers &amp; imaging retina
2025

The Curious Case of Confounding Headaches.

Case reports in rheumatology
2025

Racial differences in stroke, blindness, and mortality among Black versus non-Black patients with giant cell arteritis: an international cohort study.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2026

Dupilumab-induced eosinophilic granulomatosis with polyangiitis mimicking giant cell arteritis.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2025

Transcatheter Aortic Valve Implantation for Severe Bicuspid Aortic Stenosis With Concomitant Giant Cell Arteritis Aortitis.

JACC. Case reports
2025

CT Angiography of the Head for the Initial Assessment of Giant Cell Arteritis: Presenting Symptoms, Biopsy Outcomes and Alternative Diagnosis.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2025

The role of 18F-fluorodeoxyglucose positron emission tomography for vascular imaging.

Progress in cardiovascular diseases
2025

Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review.

BMC rheumatology
Ver todos os 5.037 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Arterite de células gigantes.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Arterite de células gigantes

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Polymyalgia Rheumatica.
    The New England journal of medicine· 2026· PMID 41812194mais citado
  2. Systematic Review and Meta-Analysis for JCS 2026 Guideline on Management of Large-Vessel Vasculitis.
    Circulation journal : official journal of the Japanese Circulation Society· 2026· PMID 41692437mais citado
  3. Hydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol.
    BMJ open· 2026· PMID 41638742mais citado
  4. Pulmonary artery aneurysm as a rare manifestation of giant cell arteritis.
    BMJ case reports· 2026· PMID 41592885mais citado
  5. Scalp necrosis and visual loss in giant cell arteritis: the importance of recognising atypical cutaneous clues.
    Practical neurology· 2026· PMID 41494871mais citado
  6. Clonal hematopoiesis of indeterminate potential and relapses in patients with giant cell arteritis.
    Rheumatology (Oxford)· 2026· PMID 41992515recente
  7. Diagnostic accuracy of ultrasound versus cranial MRI for giant cell arteritis: dependence on cardiovascular risk for ultrasound only.
    Rheumatology (Oxford)· 2026· PMID 41992505recente
  8. Correction: The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica.
    Front Med (Lausanne)· 2026· PMID 41987771recente
  9. A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis.
    Semin Arthritis Rheum· 2026· PMID 41985413recente
  10. Recognition of giant cell arteritis and calcified carotid artery atheromas in dental practice: systematic review and meta-analysis.
    Clin Oral Investig· 2026· PMID 41984118recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:397(Orphanet)
  2. OMIM OMIM:187360(OMIM)
  3. MONDO:0008538(MONDO)
  4. GARD:9615(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q707816(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Arterite de células gigantes
Compêndio · Raras BR

Arterite de células gigantes

ORPHA:397 · MONDO:0008538
Prevalência
1-9 / 100 000
Herança
Multigenic/multifactorial
CID-10
M31.6 · Outras arterites de células gigantes
CID-11
Ensaios
25 ativos
Início
Adult
Prevalência
8.9 (Germany)
MedGen
UMLS
C0039483
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades